

PRESS RELEASE

Grenchen, August 31, 2016

Excellent results with Thommen Medical implants length 6.5 mm with superhydrophilic INICELL® surface in severely atrophic posterior maxillae

Huajie Yu, Xing Wang and Lixin Qiu, Peking University School and Hospital of Stomatology, Beijing, China published in the Journal of Clinical Implant Dentistry and Related Research*:

The prospective, randomized controlled clinical study shows that the 2-year performances of short hydrophilic implants (6.5 mm) placed with osteotome sinus floor elevation procedures are similar to conventional long implants placed with lateral sinus floor elevation with bone grafting in severely atrophic posterior maxillae. Hydrophilic surfaces may be a favorable choice for patients with limited residual bone height as these implants can be loaded early in the elevated sinus, which contributes to the favorable outcomes.

Clinical Implant Dentistry and Related Research Volume 00, Number 00, 2016 (Early view online version: DOI 10.1111/cid.12439)

*Journal of Clinical Implant Dentistry and Related Research is rated with impact factor 4.152 (Ranking: # 4/89) in the listing for journals on Dentistry, Oral Surgery & Medicine 2015 JCR Science Edition.

Contact

Thommen Medical AG
Neckarsulmstrasse 28
CH-2540 Grenchen
Tel. +41 61 965 90 20
Fax +41 61 965 90 21
presse@thommenmedical.com
www.thommenmedical.com

The press release is also available online:

<http://www.thommenmedical.com/en/company/media/press-releases.html>

About Thommen Medical

Thommen Medical develops, manufactures and sells high-quality products for dental implantology, mainly the Thommen Implant System and biomaterials. Swiss precision, innovation, and functional design form the basis for all of the company's products. Thommen Medical's headquarters and private manufacturing facility is located in Grenchen, Switzerland. Thommen Medical has subsidiaries in Switzerland, Germany, Austria, United States and Canada, and is represented by distribution partners in most other major markets of Europe, Asia and the Middle East. It is currently a privately held company, with two private investor groups and Novartis being the majority stockholders.